ARTICLE | Company News

Oncologie purchases bavituximab from Avid

February 16, 2018 8:00 PM UTC

Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly Peregrine Pharmaceuticals. Avid, which transitioned to a contract development and manufacturing organization in January, will receive $8 million upfront and is eligible for $95 million in development, regulatory and commercialization milestones. Avid is also eligible for royalties. Oncologie is responsible for future research, development and commercialization of the chimeric mAb against phosphatidylserine...